Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA Shortens Regulatory Path For Antibacterials Against Multidrug Resistant Pathogens

This article was originally published in The Pink Sheet Daily

Executive Summary

Following new guidance from the European Medicines Agency, marketing approvals for antibacterials against multi-resistant bugs could be granted in Europe on expanded Phase II clinical trial data, a path that multinational Roche is keen to explore.

You may also be interested in...



Pipeline Watch: Phase III Readouts For Dry Eye, Menopause

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

UCB And Microsoft Expand AI Tie-Up Beyond COVID-19

Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.

Italfarmaco's Givinostat Encouraging In DMD, But Awaiting 2022 Pivotal Study Results

Italy’s Italfarmaco expects top-line data from its pivotal Phase III study of givinostat in Duchenne muscular dystrophy in the middle of next year, as the HDAC inhibitor continues to accrue data from the extension of its Phase II study.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel